CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


COVID-19 Antibody testingWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug2558 Trauma-informed yoga video recording Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D001008 Anxiety Disorders NIH 0.17

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Seroprevalence of SARS-CoV-2 Antibodies and Development of Immunity in a Public School Population - a Population-based Observational Study to Inform Policy Making

There is a lack of knowledge about how many children are infected with SARS-CoV-2, how often they are asymptomatic, and how long the immunity persists. The main purpose of this study is to measure antibodies to SARS-CoV-2, symptoms, and risk factors in a representative cohort of children and adolescents in the canton of Zurich, Switzerland, shortly after re-opening of the school system and thereafter. The study also investigates antibodies to SARS-CoV-2 in parents of the children and school personnel.

NCT04448717 SARS-CoV 2 COVID-19 Diagnostic Test: COVID-19 Antibody testing

Primary Outcomes

Description: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies in randomly selected 5- to 16-year-old population of school-children, their parents, and school personnel, after the peak phase of the first major wave shortly after re-opening of schools in the canton of Zürich, Switzerland.

Measure: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies

Time: at inclusion

Description: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies in randomly selected 5- to 16-year-old population of school-children and school personnel after 4-5 after recruitement in the canton of Zürich, Switzerland.

Measure: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies

Time: Month 4-5

Description: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies in randomly selected 5- to 16-year-old population of school-children and school personnel after 8-9 months after recruitment in the canton of Zürich, Switzerland.

Measure: Seroprevalence of SARS-CoV-2 IgG, IgM and/or IgA antibodies

Time: Month 8-9

Secondary Outcomes

Description: Presence of symptoms (from January 2020) suggestive of a common cold, influenza and similar upper respiratory tract infections prior to the first study visit.

Measure: Presence of self-reported symptoms

Time: at inclusion

Description: Proportion of seropositive children reporting symptoms suggestive of a common cold, influenza and similar upper respiratory tract infections between January 2020 and first study visit.

Measure: Proportion of seropositive children reporting COVID-19 related symptoms from January 2020

Time: at inclusion

Description: Presence of symptoms (from January 2020) suggestive of a common cold, influenza and similar upper respiratory tract infections during the follow-up.

Measure: Presence of self-reported symptoms

Time: within 9 months of follow-up

Description: Incidence of self-reported symptoms and SARS-CoV-2 infections after the first study visit in initially seropositive participants.

Measure: Incidence of symptoms in initially seropositive participants

Time: within 9 months of follow-up

Description: Proportion of seronegative participants of the first investigation wave who will self-report symptoms and infection with SARS-CoV-2.

Measure: Proportion of participants, seronegative at inclusion, with symptoms in the follow-up

Time: within 9 months of follow-up

Description: Potential personal (socioeconomic characteristics, health status, presence of infection in family, personal hygiene and social distancing measures) and school-level (implementation of informational, social distancing and hygiene measures at school) risk and preventive factors for SARS-CoV-2 infection prior to the study. Questionnaire includes HBSC and custom questions.

Measure: Presence of risk factors for infection at inclusion (assessment via custom questionnaire)

Time: at inclusion

Description: Potential personal (socioeconomic characteristics, health status, presence of infection in family, personal hygiene and social distancing measures) and school-level (implementation of informational, social distancing and hygiene measures at school) risk and preventive factors for SARS-CoV-2 infection during the follow-up. Questionnaire includes HBSC and custom questions.

Measure: Presence of risk factors for infection during follow-up (assessment via custom questionnaire)

Time: within 9 months of follow-up

Description: Changes in lifestyle during the lock-down, compared to prior to it: frequency and duration (in hours, daily) of physical activity, duration (in hours, daily) of sleep, duration of screen-based media-use (in hours, daily). This outcome is measured only in the children population.

Measure: Self-reported lifestyle changes of participants at inclusion

Time: at inclusion

Description: Changes in lifestyle after the lock-down and school reopening, compared to during lock-down: frequency and duration (in hours, daily) of physical activity, duration (in hours, daily) of sleep, duration of screen-based media-use (in hours, daily). This outcome is measured only in the children population.

Measure: Self-reported lifestyle changes of participants during follow-up

Time: within 9 months of follow-up

Description: Changes over the study time in mental well-being of the participants during and after the lock-down: frequency scale (never/rarely/sometimes/often/always) of self-reported stress, anxiety, self-confidence feelings in the last 7 days. This outcome is measured only in the children population.

Measure: Self-reported mental well-being (KINDL questionnaire)

Time: within 9 months of follow-up

Description: Changes over the study time in mental well-being of the participants during and after the lock-down: frequency scale (daily/weekly/monthly/rarer) of self-reported sadness, anxiety and sleeping problems (HBSC questionnaire question on mental well-being). This outcome is measured only in the children population.

Measure: Self-reported mental well-being (HBSC questionnaire)

Time: within 9 months of follow-up

Description: Changes over the study time in quality-of-life of the participants during and after the lock-down: frequency scale (never/rarely/sometimes/often/always) assessment of self-reported positive and negative social interactions with family, friends and in the school environment in the last 7 days. This outcome is measured only in the children population.

Measure: Self-reported quality of life (KINDL questionnaire)

Time: within 9 months of follow-up

Description: Prevalence of clusters of seropositive children, adolescents, and school personnel within schools and classes at baseline.

Measure: Prevalence of seropositive SARS-Cov-2 clusters in schools at inclusion

Time: at inclusion

Description: Incidence of clusters of seropositive children, adolescents, and school personnel within schools and classes during the follow-up.

Measure: Incidence of seropositive SARS-Cov-2 clusters in schools during the follow-up

Time: within 9 months of follow-up

Description: Impact of the number of children/adolescents and school personnel at a specific period (baseline, at the second and third testing date) within a school or class to the subsequent seropositivity within the same group.

Measure: Change in seropositive participants within school or class, depending on the initial proportion of seropositive participants

Time: within 9 months of follow-up

Description: Incidence of seropositive children and school personnel according to potential risk factors and preventive measures for SARS-CoV-2 infection within schools.

Measure: Effect of risk factors and preventive measures on SARS-CoV-2 infection incidence within schools

Time: within 9 months of follow-up


No related HPO nodes (Using clinical trials)